Staring at Screens Can Cause Eye Strain. Here's Tips to Prevent That
SATURDAY, Oct. 28, 2023 -- Millions of people spend hours looking at screens every day, straining their eyes.An ophthalmologist at Baylor College of Medicine in Houston offers some tips for easing both eye strain and headaches. “We focus on one... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 28, 2023 Category: General Medicine Source Type: news
AAO 2023: New Modes of Treatments and New Directions for Diabetic Macular Edema AAO 2023: New Modes of Treatments and New Directions for Diabetic Macular Edema
Dr Sunir Garg outlines several topics to be addressed at AAO 2023, including enhancements to anti-VEGF therapy and strategies for making clinical trials more representative of the general population.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2023 Category: Consumer Health News Tags: Ophthalmology MDAngle Source Type: news
AAO 2023: Anticipating New and Real-World Data in AMD AAO 2023: Anticipating New and Real-World Data in AMD
Dr Vaidehi Dedania looks ahead to the 2023 AAO meeting expecting updates from trials on geographic atrophy as well as clinical best-practices regarding therapies for exudative macular degeneration.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2023 Category: Consumer Health News Tags: Ophthalmology MDAngle Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to afliberceptVabysmo also demonstrated rapid and robust drying of retinal fluidAdditional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate isin line withother broadly used intravitreal treatmentsBasel, 27 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) an...
Source: Roche Investor Update - October 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to afliberceptVabysmo also demonstrated rapid and robust drying of retinal fluidAdditional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate isin line withother broadly used intravitreal treatmentsBasel, 27 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) an...
Source: Roche Media News - October 27, 2023 Category: Pharmaceuticals Source Type: news
Tested: Three vehicles for three different road trips
The breadth and depth of the automotive market is staggering when looked at in its entirety. There are hundreds of different models on sale from dozens of automakers from all corners of the world. All of which is at the fingertips of anyone with an internet connection and surprisingly reasonable…#subarucrosstrek #chicagoautoshow #crosstrek #normal #illinois #detroit #michigan #sidrive #subaru #eyesight (Source: Reuters: Health)
Source: Reuters: Health - October 26, 2023 Category: Consumer Health News Source Type: news
Prevent Blindness Provides Informational Resources to Professionals and the Public for November's Diabetes-related Eye Disease Awareness Month
Nonprofit organization Prevent Blindness is Offering Videos, Fact Sheets, Social Media Graphics and PowerPoint Presentations to Educate Public on the Potential Effects that Diabetes May Have on Vision CHICAGO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- A recent study, "Prevalence of Diabetic... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 25, 2023 Category: Pharmaceuticals Tags: NPT Source Type: news
Implandata Announces Appointment of New Members Dr. Adrienne Graves and Jan Willem de Cler to Join Board of Directors
HANNOVER, Germany and SAN DIEGO, USA, October 24th, 2023 -- Implandata Ophthalmic Products, an emerging ophthalmic health tech company based in Germany and USA, announced that Dr. Adrienne Graves and Mr. Jan Willem de Cler are appointed as new members of the company's Board of Directors.... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 24, 2023 Category: Pharmaceuticals Tags: PER Source Type: news
Oculopalpebral trauma in domestic violence - Abayi DAM, Assoumou PA, Matsanga OR, Brahime F, Aki TM, Mengome EM.
INTRODUCTION: Oculopalpebral trauma in domestic violence is defined as ophthalmological injuries caused by a spouse. PURPOSE: To describe the epidemiology and management of oculopalpebral injuries caused by domestic violence. PATIENTS AND M... (Source: SafetyLit)
Source: SafetyLit - October 24, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Reminder: Invitation to Roche ’s virtual Neuroscience Update IR Event
We are pleased to invite investors and analysts to participate in our virtual event onMonday,30 October2023, highlighting Roche ’s Neuroscience portfolio, including the latest data presented at ECTRIMS 2023 (Ocrevus, fenebrutinib) and CTAD 2023 (trontinemab, gamma-secretase modulator). 17:00 – 18:15 CET / 16:00 - 17:15GMT12:00 – 1:15 pm EDT / 9:00 – 10:15 am PDT The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 16:00 CET on the day of the event.>click here AgendaWelcomeBruno Eschli, Head of Investor Relati...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news
Optician's warning coloured contact lenses could lead to 'possible blindness'
As Halloween approaches, many may reach for coloured lenses to complete their look, but this could be dangerous. (Source: Daily Express - Health)
Source: Daily Express - Health - October 22, 2023 Category: Consumer Health News Source Type: news
AI Tool Peers Into Eyes To Detect Early Heart Attack, Glaucoma And Parkinson's Risk Factors Before Patients Show Symptoms
Researchers at Moorfields Eye Hospital and UCL Institute of Ophthalmology (IoO) have developed an artificial intelligence (AI) model called RETFound that can predict heart attack risks by examining a patient's eyes. The UCL Institute of Ophthalmology is part of the Faculty of Brain Sciences of…#retfound #ucl #irish #ghana #tanzania #eastafrican #nhs #clinicians #starpaxbiopharma #airbnb (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2023 Category: Consumer Health News Source Type: news
FDA Approves Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia
PONTE VEDRA, Fla., Oct. 18, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 18, 2023 Category: Drugs & Pharmacology Source Type: news
Eye Drops for Presbyopia Win FDA Approval
(MedPage Today) -- The FDA approved pilocarpine hydrochloride ophthalmic solution (Qlosi) for adults with presbyopia, according to a statement from Orasis Pharmaceuticals.
The approval allows for daily or as-needed use, up to twice a day. Orasis... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 18, 2023 Category: American Health Source Type: news
Enterprise imaging: What is the market opportunity beyond radiology?
The concept of an enterprise imaging strategy was coined over a decade ago, however, it’s only in recent years that the expansion beyond “enterprise radiology” has truly begun. The total market for IT across those nine specialties included in Signify Research’s report reached $6.6 billion in 2022; however, only 20% of market revenue was associated with enterprise deals. When digging deeper into which specialties led the enterprise trend, radiology represented 71% of the total enterprise imaging IT market. As demonstrated in the graph below, radiology and cardiology are expected to continue dominating the market op...
Source: AuntMinnie.com Headlines - October 18, 2023 Category: Radiology Authors: Amy Thompson Tags: PACS/VNA Technology Review Source Type: news
